Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

The deal gives MSD exclusive rights to the HRS-5346 candidate outside the Greater China region and also includes milestone payments tied to development, regulatory, and commercial targets that ...

Merck last week signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals to test its experimental Lp(a) pill called HRS-5346. (This story has been corrected to reflect a total of 141 ...

Moreover, Merck has entered into a new licensing agreement with Jiangsu Hengrui Pharmaceuticals, granting it exclusive rights to develop and commercialize HRS-5346, an oral small molecule Lp(a ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...

Merck last week signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals to test its experimental Lp(a) pill called HRS-5346.